Description
Indication & Scope
Crizotinib Capsules (Xalkori®) is first-generation multi-target tyrosine kinase inhibitor. It selectively inhibits ALK, ROS1 and c-MET kinase activity, blocks downstream cell proliferation signal pathways, suppresses growth and metastasis of ALK/ROS1 fusion-positive lung tumor cells.
- Mechanism
Inhibit ALK/ROS1/c-MET kinase, block oncogenic signaling, restrain tumor proliferation - Drug class
First-generation oral ALK/ROS1 targeted anti-tumor TKI - Clinical use
ALK-positive or ROS1-positive locally advanced/metastatic non-small cell lung cancer
| Generic Name | Crizotinib Capsules |
| Brand Name | Xalkori® |
| Ingredient | Crizotinib |
| Dosage Form | Hard Gelatin Capsules |
| Package | 200mg*60 capsules/bottle |
| Conditions Treated | Locally advanced or metastatic NSCLC positive for ALK rearrangement detected by validated tests;Advanced NSCLC positive for ROS1 rearrangement |
| Taboos | Pregnancy/lactation, congenital long QT syndrome, hypersensitivity to crizotinib or excipients |
| Place of origin | Germany |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Store below 30°C, keep tightly closed |
| Manufacturer | Pfizer Manufacturing Deutschland GmbH |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20171012 |
| Approval Date | April 9, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Standard dose: 250mg oral twice daily, swallow whole capsule, with or without food;Severe renal impairment (CLcr＜30mL/min, non-dialysis): 250mg once daily;Dose reduction: 1st:200mg twice daily; 2nd:250mg once daily; discontinue permanently if intolerable
Time: Continuous administration until disease progression or intolerable toxicity; test ALK/ROS1 positivity before treatment
Interaction: Avoid strong CYP3A4 inhibitors/inducers, QT-prolonging drugs and bradycardia-inducing agents
Side effects: Visual disturbance, nausea, diarrhea, edema, elevated liver enzymes, fatigue, bradycardia; severe risks include hepatotoxicity, interstitial lung disease, QT prolongation
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What generation ALK-TKI is crizotinib?
First-generation ALK tyrosine kinase inhibitor.
What mandatory test should be completed before medication?
Validated ALK or ROS1 gene rearrangement detection.
What targets does crizotinib mainly inhibit?
ALK, ROS1 and c-MET kinases.
What cardiac indexes need regular monitoring?
ECG, heart rate and serum electrolytes.
Xalkori® | Crizotinib Capsules | ALK and NSCLC | DengYueRX
INN: Crizotinib
Indications: ALK (Anaplastic Lymphoma Kinase) and NSCLC (Non-Small Cell Lung Cancer)
Dosage Form: Hard Gelatin Capsules
Strength: 200mg/Capsule
Original price was: $1,641.18.$1,395.00Current price is: $1,395.00.
